Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (AVHHL) Long-Term Investments (2021 - 2023)

Historic Long-Term Investments for AVITA Medical (AVHHL) over the last 3 years, with Q2 2023 value amounting to $2.8 million.

  • AVITA Medical's Long-Term Investments fell 5915.76% to $2.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.8 million, marking a year-over-year decrease of 5915.76%. This contributed to the annual value of $6.9 million for FY2022, which is N/A changed from last year.
  • As of Q2 2023, AVITA Medical's Long-Term Investments stood at $2.8 million, which was down 5915.76% from $4.2 million recorded in Q1 2023.
  • AVITA Medical's 5-year Long-Term Investments high stood at $19.8 million for Q3 2021, and its period low was $2.8 million during Q2 2023.
  • In the last 3 years, AVITA Medical's Long-Term Investments had a median value of $6.8 million in 2022 and averaged $9.5 million.
  • As far as peak fluctuations go, AVITA Medical's Long-Term Investments crashed by 7973.84% in 2022, and later plummeted by 5915.76% in 2023.
  • Over the past 3 years, AVITA Medical's Long-Term Investments (Quarter) stood at $19.7 million in 2021, then plummeted by 64.81% to $6.9 million in 2022, then crashed by 60.26% to $2.8 million in 2023.
  • Its last three reported values are $2.8 million in Q2 2023, $4.2 million for Q1 2023, and $6.9 million during Q4 2022.